Literature DB >> 20715177

Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts.

Lynett Danks1, Sarita Workman, David Webster, Nicole J Horwood.   

Abstract

Mutations in Bruton's tyrosine kinase (Btk) cause the B-cell disorder X-linked agammaglobulinaemia (XLA) in humans, but the effect of Btk deficiency in human bone health has not been investigated previously. In this study, we show that human Btk-deficient osteoclasts are defective at resorption activity in vitro owing to a dysregulation of the actin cytoskeletal function. Contrary to expectation, XLA patients did not exhibit increased bone density or alterations in serum markers of bone turnover, indicating that a potential compensation mechanism normalizes bone homeostasis. In contrast to the bone turnover markers, the levels of inflammatory cytokines interleukin 6 (IL-6), IL-1β, and tumor necrosis factor α (TNF-α) were significantly elevated in XLA patients' serum compared with control individuals. Supplementation of osteoclast cultures from normal and XLA subjects with serum from XLA patients or recombinant inflammatory cytokines IL-6, IL-1β, and TNF-α resulted in a stimulation of osteoclast activity in vitro, whereas the addition of cytokine-neutralizing antibodies inhibited this stimulatory effect, confirming that elevated inflammatory cytokines in XLA serum heightened osteoclast activity in vitro. This study provides novel evidence that Btk signaling is crucial for optimal actin cytoskeletal organization and lacunar resorption in isolated osteoclasts. In XLA patients, however, these inherent osteoclast defects are corrected by increased inflammatory cytokine levels, restoring osteoclast activity and leading to the normalization of bone density.
© 2011 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20715177     DOI: 10.1002/jbmr.210

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  18 in total

Review 1.  Toll-like receptor signaling in primary immune deficiencies.

Authors:  Paul J Maglione; Noa Simchoni; Charlotte Cunningham-Rundles
Journal:  Ann N Y Acad Sci       Date:  2015-04-30       Impact factor: 5.691

2.  Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

Authors:  Yu-Tzu Tai; Betty Y Chang; Sun-Young Kong; Mariateresa Fulciniti; Guang Yang; Yolanda Calle; Yiguo Hu; Jianhong Lin; Jian-Jun Zhao; Antonia Cagnetta; Michele Cea; Michael A Sellitto; Mike Y Zhong; Qiuju Wang; Chirag Acharya; Daniel R Carrasco; Joseph J Buggy; Laurence Elias; Steven P Treon; William Matsui; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-06-11       Impact factor: 22.113

3.  Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines.

Authors:  Thomas U Marron; Monica Martinez-Gallo; Joyce E Yu; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2011-11-16       Impact factor: 10.793

Review 4.  Feedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8.

Authors:  Lionel B Ivashkiv; Baohong Zhao; Kyung-Hyun Park-Min; Masamichi Takami
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

Review 5.  Pathways for bone loss in inflammatory disease.

Authors:  Tobias Braun; Georg Schett
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

6.  Retrospective study of 98 patients with X-linked agammaglobulinemia complicated with arthritis.

Authors:  Ran Qing-Qi; Li Ya-Wen; Chen Huan; Zhang Yu; An Yun-Fei; Tang Xue-Mei; Zhao Xiao-Dong; Zhang Zhi-Yong
Journal:  Clin Rheumatol       Date:  2022-02-16       Impact factor: 3.650

7.  Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Authors:  Rakesh Bam; Wen Ling; Sharmin Khan; Angela Pennisi; Sathisha Upparahalli Venkateshaiah; Xin Li; Frits van Rhee; Saad Usmani; Bart Barlogie; John Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Am J Hematol       Date:  2013-03-28       Impact factor: 10.047

8.  A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.

Authors:  H Eda; L Santo; D D Cirstea; A J Yee; T A Scullen; N Nemani; Y Mishima; P R Waterman; S Arastu-Kapur; E Evans; J Singh; C J Kirk; W F Westlin; N S Raje
Journal:  Leukemia       Date:  2014-02-12       Impact factor: 11.528

Review 9.  Altered bone biology in psoriatic arthritis.

Authors:  Homaira Rahimi; Christopher T Ritchlin
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

10.  OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis.

Authors:  Emily Gwyer Findlay; Lynett Danks; Jodie Madden; Mary M Cavanagh; Kay McNamee; Fiona McCann; Robert J Snelgrove; Stevan Shaw; Marc Feldmann; Peter Charles Taylor; Nicole J Horwood; Tracy Hussell
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.